{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.7596","upperLimit":"12.7710","value":"4.7404"},{"groupId":"OG001","lowerLimit":"5.0002","upperLimit":"14.2661","value":"8.4459"},{"groupId":"OG002","lowerLimit":"8.6950","upperLimit":"17.3962","value":"12.2987"},{"comment":"As pre-specified in the SAP, Geometric Mean and 95% confidence interval (CI) were not calculated if less than 3 concentration were available or if the below the lower limit of quantification (LLOQ) was greater than (\\>) 1/3.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"groupId":"OG004","lowerLimit":"11.1744","upperLimit":"38.3636","value":"20.7048"},{"groupId":"OG005","lowerLimit":"14.6913","upperLimit":"44.5878","value":"25.5940"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"25"}],"units":"Participants"}],"description":"Certolizumab Pegol (CZP) plasma concentration level was measured in ug/mL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received CZP 50 milligrams (mg) sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q4W (maintenance dose) from Week 8 onwards.","id":"OG000","title":"Reduced CZP Dose -Weight Group: 10 - <20 kg"},{"description":"Participants received CZP 100 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG001","title":"Reduced CZP Dose - Weight Group: 20 - <40 kg"},{"description":"Participants received CZP 200 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 100 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG002","title":"Reduced CZP Dose - Weight Group: >=40 kg"},{"description":"Participants received CZP 100 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 50 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG003","title":"Original CZP Dose - Weight Group: 10 - <20 kg"},{"description":"Participants received CZP 200 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 100 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG004","title":"Original CZP Dose - Weight Group: 20 - <40 kg"},{"description":"Participants received CZP 400 mg sc Q2W at Weeks 0, 2, and 4 (loading dose) followed by CZP 200 mg sc Q2W (maintenance dose) from Week 6 onwards.","id":"OG005","title":"Original CZP Dose - Weight Group: >=40 kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The Pharmacokinetic Per-Protocol (PK-PP) Set was a subset of the SS consisting of those study participants who took at least 1 dose of study medication, provided measurable plasma CZP concentration samples (with recorded sampling date/time or for which date/time can be reasonably assumed). Here, \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 48","title":"Certolizumab Pegol (CZP) Plasma Concentration Level at Week 48","type":"PRIMARY","unitOfMeasure":"ug/ml"}